122 related articles for article (PubMed ID: 35253251)
1. Population pharmacokinetics analyses of rifampicin in adult and children populations: A systematic review.
Muda MR; Harun SN; Syed Sulaiman SA; Sheikh Ghadzi SM
Br J Clin Pharmacol; 2022 Jul; 88(7):3132-3152. PubMed ID: 35253251
[TBL] [Abstract][Full Text] [Related]
2. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Clozapine: A Systematic Review.
Albitar O; Harun SN; Zainal H; Ibrahim B; Sheikh Ghadzi SM
Biomed Res Int; 2020; 2020():9872936. PubMed ID: 31998804
[TBL] [Abstract][Full Text] [Related]
4. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid.
Marsot A; Ménard A; Dupouey J; Muziotti C; Guilhaumou R; Blin O
Br J Clin Pharmacol; 2017 May; 83(5):1039-1047. PubMed ID: 27813241
[TBL] [Abstract][Full Text] [Related]
6. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.
Zhang C; Denti P; Decloedt EH; Ren Y; Karlsson MO; McIlleron H
Br J Clin Pharmacol; 2013 Nov; 76(5):741-51. PubMed ID: 23432610
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.
Stott KE; Pertinez H; Sturkenboom MGG; Boeree MJ; Aarnoutse R; Ramachandran G; Requena-Méndez A; Peloquin C; Koegelenberg CFN; Alffenaar JWC; Ruslami R; Tostmann A; Swaminathan S; McIlleron H; Davies G
J Antimicrob Chemother; 2018 Sep; 73(9):2305-2313. PubMed ID: 29701775
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
[TBL] [Abstract][Full Text] [Related]
9. The Population Pharmacokinetics of Rifampicin in Japanese Pulmonary Tuberculosis Patients.
Nishimura T; Kohno H; Nagai H; Maruoka D; Koike Y; Kobayashi M; Atsuda K
Drug Res (Stuttg); 2020 May; 70(5):199-205. PubMed ID: 32193878
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.
Milán Segovia RC; Domínguez Ramírez AM; Jung Cook H; Magaña Aquino M; Vigna Pérez M; Brundage RC; Romano Moreno S
J Clin Pharm Ther; 2013 Feb; 38(1):56-61. PubMed ID: 23167603
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
Li J; Al-Huniti N; Henningsson A; Tang W; Masson E
Br J Clin Pharmacol; 2017 Aug; 83(8):1723-1733. PubMed ID: 28213941
[TBL] [Abstract][Full Text] [Related]
13. A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.
Medellin-Garibay SE; Huerta-García AP; Rodríguez-Báez AS; Magaña-Aquino M; Ortiz-Álvarez A; Portales-Pérez DP; Milán-Segovia RDC; Romano-Moreno S
Tuberculosis (Edinb); 2020 Sep; 124():101982. PubMed ID: 32810723
[TBL] [Abstract][Full Text] [Related]
14. The impact of diabetes mellitus on the pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-analysis study.
Metwally AS; El-Sheikh SMA; Galal AAA
Diabetes Metab Syndr; 2022 Feb; 16(2):102410. PubMed ID: 35144181
[TBL] [Abstract][Full Text] [Related]
15. Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.
Roth WJ; Kissinger CB; McCain RR; Cooper BR; Marchant-Forde JN; Vreeman RC; Hannou S; Knipp GT
AAPS J; 2013 Jul; 15(3):763-74. PubMed ID: 23595360
[TBL] [Abstract][Full Text] [Related]
16. Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses.
Methaneethorn J; Leelakanok N
Seizure; 2020 Nov; 82():133-147. PubMed ID: 33060011
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin: a review of population pharmacokinetic analyses.
Marsot A; Boulamery A; Bruguerolle B; Simon N
Clin Pharmacokinet; 2012 Jan; 51(1):1-13. PubMed ID: 22149255
[TBL] [Abstract][Full Text] [Related]
19. Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations.
Rasool MF; Khalid S; Majeed A; Saeed H; Imran I; Mohany M; Al-Rejaie SS; Alqahtani F
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31694244
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
